Document is current
Any future updates will be listed below
-
Authors
Holten, Kristina I. Aass https://orcid.org/0009-0007-4041-2623
Bernklev, Tomm
Opheim, Randi
Olsen, Bjørn C.
Johansen, Ingunn
Strande, Vibeke
Boyar, Raziye
Hovde, Øistein
Torp, Roald
Bengtson, May-Bente
Aabrekk, Tone B.
Detlie, Trond Espen
Frigstad, Svein Oskar
Kristensen, Vendel A.
Hagen, Milada
Henriksen, Magne
Huppertz-Hauss, Gert
Høivik, Marte Lie
Jelsness-Jørgensen, Lars-Petter
-
Funding
Funding for this research was provided by:
Østfold Hospital Trust (Project number AB3526)
Takeda Pharmaceuticals International
Pfizer UK
Tillotts Pharma
University of Oslo
- License Information
-
More Information
Article History
Received: 8 September 2025
Accepted: 31 December 2025
First Online: 12 January 2026
Declarations
:
: T.B, R.O, B.C.O, I.J, M.B.B, T.B.A, R.T, M.Ha, Ø.H, R.B, M.He, G.H.H, L.P.J.J and K.A.H. declare that they have no conflicts of interest. T.E.D: Served as a speaker, consultant or advisory board member for AbbVie, Ferring, Johnson&Johnsen, Pfizer, Pharmacosmos, Takeda, Tillotts, and Vifor Pharma. He has received unrestricted research grants from AbbVie, and Pharmacosmos. S.O.F: Personal fees from Takeda, Galapagos, Jansen-Cilag, Abbvie, Pharmacosmos and Bristol-Myers-Squibb. V.S: Sponsored by funds from Takeda. V.A.K: Consultant for Janssen-Cilag, scientific advisory board and consultant for Takeda, speaker for Thermo Fischer, advisory board for Tillotts Pharma. M.L.H: Investigator-initiated research grants from Takeda, Pfizer, Tilllotts, Ferring and Janssen. Speaker honoraria from Takeda, Tillotts, Ferring, AbbVie, Galapagos, MSD and Meda. Advisory board for Takeda, Galapagos, MSD, Lilly, Janssen, Pfizer and AbbVie.
: The IBSEN III study was approved by the Southeast Regional Committee for Medical and Health Research Ethics (Ref 2015/946–3). Signed informed consent was obtained from all patients before study inclusion, with the possibility to withdraw consent at any point during the observational period.
